Tuesday, 21 January 2020

Zuellig Pharma enters into strategic partnership with Eli Lilly

24 October 2019 | News

To market, sell and distribute the healthcare manufacturer's existing and new products in Malaysia and Thailand

image credit- istock.com

image credit- istock.com

Zuellig Pharma, a leading healthcare service provider in Asia, is pleased to announce two new strategic partnerships with Eli Lilly and Company (Lilly) to market, sell and distribute the healthcare manufacturer's existing and new products in Malaysia and Thailand.

Lilly is a global healthcare company with a heritage of more than 140 years, committed to creating high-quality life-changing medicines that meet real needs to make life better for people around the world. In both Malaysia and Thailand, it has proudly served healthcare professionals and their patients with innovative medicines in the areas of diabetes, oncology, men's health, bone health, diseases impacting the central nervous system and immunology with several leading brands in the market.

"We are excited to represent Lilly's innovative portfolio of products to the communities in both countries. Our team is also committed to launch new products from Lilly to meet the evolving healthcare needs in the region and to ensure patients will get access to the healthcare they need," said John Graham, SVP Commercial Solutions Zuellig Pharma.

As one of the largest healthcare services groups in Asia, Zuellig Pharma aims to continue establishing new strategic alliances to deliver on the promise of making healthcare more accessible in the region. Under this new business model, Zuellig Pharma intends to grow Lilly's innovative products across a number of diverse therapeutic categories. In doing so, Zuellig Pharma will develop world class capabilities in Diabetes, Oncology, Immunology and CNS.

"We are truly excited about commencing a strategic partnership with Zuellig Pharma in several ASEAN markets. Zuellig Pharma is a partner that shares our goal of developing a diverse and inclusive workforce delivering high performance with high integrity. Our teams in Lilly Malaysia and Lilly Thailand will work closely with Zuellig Pharma's leadership to ensure that we continue to bring new innovative products for the benefit of patients in this region," said Rehan Saghir, General Manager for Lilly ASEAN.

Together, Zuellig Pharma and Lilly look forward to continue to serve and improve the lives of patients with Lilly's existing and new innovations in Diabetes, Oncology, Immunology and Pain in the years to come.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is 2020 demanding timely action of technology adoption in healthcare?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls